Search
Pipendoxifene
go.drugbank.com/drugs/DB05414InvestigationalPipendoxifene is a new 2-phenyl indole selective estrogen receptor modulators (SERM )that exhibits an excellent preclinical pharmacological profile and was selected for further development as a treatment
Daleuton
go.drugbank.com/drugs/DB00154InvestigationalNutraceuticalA 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5.
Calcifediol
go.drugbank.com/drugs/DB00146ApprovedInvestigationalNutraceuticalThe major circulating metabolite of vitamin D3 (cholecalciferol). It is produced in the liver and is the best indicator of the body's vitamin D stores. It is effective in the treatment of rickets and osteomalacia, both in azotemic and no...
Nelfinavir
go.drugbank.com/drugs/DB00220ApprovedInvestigationalNelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the...
Sugemalimab
go.drugbank.com/drugs/DB16641ApprovedInvestigationalSugemalimab is a fully human, full-length anti-programmed death-ligand 1 (PD-L1) monoclonal antibody (of the IgG4 isotype) discovered by CStone Pharmaceuticals. The antibody is produced in Chinese hamster ovary cells by recombinant DNA t...
Vismodegib
go.drugbank.com/drugs/DB08828ApprovedInvestigationalVismodegib is an orally active small molecule that inhibits the hedgehog signaling pathway by binding to and inhibiting the transmembrane protein smoothened homologue (SMO). It was discovered by high-throughput screening of a library of ...
Cyclizine
go.drugbank.com/drugs/DB01176ApprovedWithdrawnA histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935)
Aficamten
go.drugbank.com/drugs/DB18490ApprovedInvestigationalAficamten is a cardiac myosin inhibitor. Approved by the FDA on December 19, 2025, aficamten is indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symp...
CIGB-258 peptide
go.drugbank.com/drugs/DB15809ExperimentalAs of 2020, The Center for Genetic Engineering and Biotechnology (CIGB) in Havana, Cuba, is testing the treatment efficacy of this peptide in patients with COVID-19 who are under intensive therapy regimens
Laquinimod
go.drugbank.com/drugs/DB06685InvestigationalIt is currently under development in phase III trials for treatment of multiple sclerosis as an oral therapy, like fingolimod.